ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

CMS Final Rule Imposes 6 Percent Cut On Physician Fees Over Four Years

November 6, 2009

In Brief: Visco Elected Chairman of DOD Panel; Breast Cancer Stamp Raises $4.9 Million

February 19, 1999

In Brief: Control Grant Review committee Out Of Grants Division Provisional Training Announcement Due

October 10, 1975

In Brief: Staff, Subcommittee Reports Due At NCAB June Meet; CCIRC to Sponsor Symposium On Epidemiology On Oct.

June 6, 1975

In Brief: NIH gives Advisors $50 Raise, Effective April 1, No Fooling

March 12, 1999

Clearinghouse Opens With Predictable Controversy; Brown Urges ‘Open Minds’

November 12, 1976